Givinostat
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Givinostat?
Summarize this article for a 10 year old
Givinostat, sold under the brand name Duvyzat is a medication used for the treatment of Duchenne muscular dystrophy.[1][2] It is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities.[3] It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle.[2]
Clinical data | |
---|---|
Trade names | Duvyzat |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.258.524 |
Chemical and physical data | |
Formula | C24H27N3O4 |
Molar mass | 421.497 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
The most common side effects include diarrhea, abdominal pain, a decrease in platelets—which can lead to increased bleeding—nausea/vomiting, an increase in triglycerides (a type of fat in the body) and fever.[2]
Givinostat was approved for medical use in the United States in March 2024.[2][4] Givinostat is the first nonsteroidal medication approved by the FDA to treat people with all genetic variants of Duchenne Muscular Dystrophy.[2]